Cost-effectiveness of pirfenidone compared to all available strategies for the treatment of idiopathic pulmonary fibrosis in France

• Váldodahkkit: Emilie Clay (Dahkki), Olivier Cristeau (Dahkki), Romain Chafaie (Dahkki), Alexandrina Pinta (Dahkki), Benjamin Mazaleyrat (Dahkki), Vincent Cottin (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Taylor & Francis Group, 2019-01-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Objective: To update the health economic evaluation of pirfenidone in the treatment of idiopathic pulmonary fibrosis (IPF) compared to all available alternatives strategies (Best supportive care - BSC and nintedanib), based on a cost-utility model previously validated by the CEESP's (French Com...